| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A J Hampson, M Grimaldi, M Lolic, D Wink, R Rosenthal, J Axelro. Neuroprotective antioxidants from marijuana. Annals of the New York Academy of Sciences. vol 899. 2000-07-13. PMID:10863546. |
using cyclic voltametry and a fenton reaction based system, it was demonstrated that cannabidiol, thc and other cannabinoids are potent antioxidants. |
2000-07-13 |
2023-08-12 |
rat |
| A J Hampson, M Grimaldi, M Lolic, D Wink, R Rosenthal, J Axelro. Neuroprotective antioxidants from marijuana. Annals of the New York Academy of Sciences. vol 899. 2000-07-13. PMID:10863546. |
as evidence that cannabinoids can act as an antioxidants in neuronal cultures, cannabidiol was demonstrated to reduce hydroperoxide toxicity in neurons. |
2000-07-13 |
2023-08-12 |
rat |
| S J Watson, J A Benson, J E Jo. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Archives of general psychiatry. vol 57. issue 6. 2000-06-07. PMID:10839332. |
it called for heavier investment in research on the biology of cannabinoid systems, careful clinical studies of cannabinoids in clinical syndromes, analysis of cannabinoids' psychological effects on symptoms, and evaluations of the health consequences of heavy marijuana use; recommends against the use of smoked marijuana in medicine and for the development of a medical cannabinoid inhaler; and recommends that compassionate use of marijuana be considered under carefully reviewed protocols. |
2000-06-07 |
2023-08-12 |
Not clear |
| F Chaperon, M H Thiébo. Behavioral effects of cannabinoid agents in animals. Critical reviews in neurobiology. vol 13. issue 3. 2000-06-02. PMID:10803637. |
the identification of delta9-tetrahydrocannabinol (delta9-thc) as the major active component of marijuana (cannabis sativa), the recent emergence of potent synthetic ligands and the identification of anandamide and sn-2 arachidonylglycerol as putative endogenous ligands for cannabinoid receptors in the brain, have contributed to advancing cannabinoid pharmacology and approaching the neurobiological mechanisms involved in physiological and behavioral effects of cannabinoids. |
2000-06-02 |
2023-08-12 |
Not clear |
| J Molnár, D Szabó, R Pusztai, I Mucsi, L Berek, I Ocsovszki, E Kawata, Y Shoyam. Membrane associated antitumor effects of crocine-, ginsenoside- and cannabinoid derivates. Anticancer research. vol 20. issue 2A. 2000-06-01. PMID:10810367. |
some cannabinoid derivatives such as cannabinol, cannabispirol and cannabidiol increased drug accumulation, while cannabidiolic acid, delta-9-thc and tetrahydro-cannabidiolic acid reduced drug accumulation of the human mdr1-gene transfected mouse lymphoma cells. |
2000-06-01 |
2023-08-12 |
mouse |
| A F Hoffman, C R Lupic. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 20. issue 7. 2000-05-16. PMID:10729327. |
the localization of cannabinoid (cb) receptors to gabaergic interneurons in the hippocampus indicates that cbs may modulate gabaergic function and thereby mediate some of the disruptive effects of marijuana on spatial memory and sensory processing. |
2000-05-16 |
2023-08-12 |
rat |
| K Soderstrom, F Johnso. CB1 cannabinoid receptor expression in brain regions associated with zebra finch song control. Brain research. vol 857. issue 1-2. 2000-05-04. PMID:10700562. |
cannabinoids have been used for millennia through various preparations of cannabis sativa. |
2000-05-04 |
2023-08-12 |
Not clear |
| A Holdcrof. Adverse effects of cannabis and cannabinoids. British journal of anaesthesia. vol 84. issue 3. 2000-05-04. PMID:10793614. |
adverse effects of cannabis and cannabinoids. |
2000-05-04 |
2023-08-12 |
Not clear |
| D Baker, G Pryce, J L Croxford, P Brown, R G Pertwee, J W Huffman, L Laywar. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. vol 404. issue 6773. 2000-04-03. PMID:10716447. |
this provides a rationale for patients' indications of the therapeutic potential of cannabis in the control of the symptoms of multiple sclerosis, and provides a means of evaluating more selective cannabinoids in the future. |
2000-04-03 |
2023-08-12 |
mouse |
| F Rakhshan, T A Day, R D Blakely, E L Barke. Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. The Journal of pharmacology and experimental therapeutics. vol 292. issue 3. 2000-03-17. PMID:10688610. |
anandamide (n-arachidonylethanolamide) is an endogenous cannabinoid that mimics the pharmacologic effects of delta(9)-tetrahydrocannabinol, the major bioactive substance in marijuana. |
2000-03-17 |
2023-08-12 |
Not clear |
| C H Ashto. Adverse effects of cannabis and cannabinoids. British journal of anaesthesia. vol 83. issue 4. 2000-03-02. PMID:10673884. |
adverse effects of cannabis and cannabinoids. |
2000-03-02 |
2023-08-12 |
Not clear |
| M A ElSohly, S A Ross, Z Mehmedic, R Arafat, B Yi, B F Banaha. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. Journal of forensic sciences. vol 45. issue 1. 2000-02-25. PMID:10641915. |
potency trends of delta9-thc and other cannabinoids in confiscated marijuana from 1980-1997. |
2000-02-25 |
2023-08-12 |
Not clear |
| M A ElSohly, S A Ross, Z Mehmedic, R Arafat, B Yi, B F Banaha. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. Journal of forensic sciences. vol 45. issue 1. 2000-02-25. PMID:10641915. |
the analysis of 35,312 cannabis preparations confiscated in the usa over a period of 18 years for delta-9-tetrahydrocannabinol (delta9-thc) and other major cannabinoids is reported. |
2000-02-25 |
2023-08-12 |
Not clear |
| M A ElSohly, S A Ross, Z Mehmedic, R Arafat, B Yi, B F Banaha. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. Journal of forensic sciences. vol 45. issue 1. 2000-02-25. PMID:10641915. |
other major cannabinoids [cannabidiol (cbd), cannabinol (cbn), and cannabichromene (cbc)] showed no significant change in their concentration over the years. |
2000-02-25 |
2023-08-12 |
Not clear |
| E S Onaivi, G Chaudhuri, A S Abaci, M Parker, D H Manier, P R Martin, J R Hubbar. Expression of cannabinoid receptors and their gene transcripts in human blood cells. Progress in neuro-psychopharmacology & biological psychiatry. vol 23. issue 6. 2000-02-03. PMID:10621950. |
normal human volunteers who do not use marijuana have genes that encode for the marijuana (cannabinoid) receptor proteins. |
2000-02-03 |
2023-08-12 |
human |
| G A Bohme, M Laville, C Ledent, M Parmentier, A Imperat. Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors. Neuroscience. vol 95. issue 1. 2000-01-31. PMID:10619457. |
marijuana is known to affect learning and memory in humans, and cannabinoids block long-term potentiation in the hippocampus, a model for the synaptic changes that are believed to underlie memory at the cellular level. |
2000-01-31 |
2023-08-12 |
mouse |
| Z H Song, C A Slowe. Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. The Journal of pharmacology and experimental therapeutics. vol 292. issue 1. 2000-01-27. PMID:10604940. |
it is known that marijuana smoking and administration of natural cannabinoids reduce intraocular pressure. |
2000-01-27 |
2023-08-12 |
Not clear |
| Z Járai, J A Wagner, K Varga, K D Lake, D R Compton, B R Martin, A M Zimmer, T I Bonner, N E Buckley, E Mezey, R K Razdan, A Zimmer, G Kuno. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proceedings of the National Academy of Sciences of the United States of America. vol 96. issue 24. 2000-01-06. PMID:10570211. |
here we show that "abnormal cannabidiol" (abn-cbd) is a neurobehaviorally inactive cannabinoid that does not bind to cb1 receptors, yet causes sr141716a-sensitive hypotension and mesenteric vasodilation in wild-type mice and in mice lacking cb1 receptors or both cb1 and cb2 receptors. |
2000-01-06 |
2023-08-12 |
mouse |
| R G Pertwe. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forschende Komplementarmedizin. vol 6 Suppl 3. 2000-01-05. PMID:10575283. |
cannabis and cannabinoids: pharmacology and rationale for clinical use. |
2000-01-05 |
2023-08-12 |
Not clear |
| R G Pertwe. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forschende Komplementarmedizin. vol 6 Suppl 3. 2000-01-05. PMID:10575283. |
for the therapeutic potential of cannabis or cb1 receptor agonists to be fully exploited, it will be important to establish objectively and conclusively (a) whether these agents have efficacy against selected symptoms that is of clinical significance and, if so, whether the benefits outweigh the risks, (b) whether cannabis has therapeutic advantages over individual cannabinoids, (c) whether there is a need for additional drug treatments to manage any of the disorders against which cannabinoids are effective, and (d) whether it will be possible to develop drugs that have reduced psychotropic activity and yet retain the ability to act through cb1 receptors to produce their sought-after effects. |
2000-01-05 |
2023-08-12 |
Not clear |